CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Filgrastim +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000801
NCT00000801Phase 2Completed

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 1, 2012

In Brief

A Phase 2 clinical trial evaluating Filgrastim, Vincristine sulfate, and 4 other interventions for Lymphoma, Non-Hodgkin and HIV Infections. Completed, across 7 sites.

Detailed Summary

To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionApr 1, 1998
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Filgrastimdrug

Vincristine sulfatedrug

Doxorubicin hydrochloridedrug

Cyclophosphamidedrug

Cytarabinedrug

Dexamethasonedrug